ASP 7991

Drug Profile

ASP 7991

Alternative Names: ASP7991

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class
  • Mechanism of Action Calcium-sensing receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Secondary hyperparathyroidism

Most Recent Events

  • 31 May 2015 Discontinued - Phase-II for Secondary hyperparathyroidism in Japan (PO)
  • 01 Nov 2014 Astellas Pharma completes a phase II trial for Secondary hyperparathyroidism in Japan (NCT02133404)
  • 09 May 2014 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top